Science news

<<  return


         The addition of spironolactone to patients with resistant hypertension currently treated with renin-angiotensin-aldosterone system  blockers, calcium-channel blockers  and a thiazidelike diuretic resulted in a significant reduction in systolic blood pressure, according to the results of a new study.

The addition of spironolactone resulted in larger reductions in systolic blood pressure than adding the beta-blocker bisoprolol, the alpha-adrenergic blocker doxazosin, or placebo.

The results of the study, known as Optimal Treatment of Drug-Resistant Hypertension—PATHWAY2, were presented tat the the European Society of Cardiology (ESC) 2015 Congress .

The average home systolic blood pressure on spironolactone was 134.9 mm Hg, which is just below the target level of 135 mm Hg.  Investigators were controlling a large percentage of these patients previously defined as [having] uncontrollable hypertension.